Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Potassium-competitive acid blockers for the management of gastroesophageal reflux disease

Nature Reviews Gastroenterology & Hepatology (2025)Cite this article

Subjects

Potassium-competitive acid blockers (P-CABs) overcome the limitations of proton pump inhibitors by providing faster, longer and stronger acid suppression without meal timing. Evidence shows that P-CABs are non-inferior for the management of mild erosive oesophagitis and superior for severe erosive oesophagitis, whereas data for non-erosive reflux disease remain conflicting.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Potassium-competitive acid blockers and proton pump inhibitors in GERD management.

References

  1. Savarino, E. et al. Expert consensus document: advances in the physiological assessment and diagnosis of GERD. Nat. Rev. Gastroenterol. Hepatol. 14, 665–676 (2017).

    Article  PubMed  Google Scholar 

  2. Eusebi, L. H. et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 67, 430–440 (2018).

    Article  PubMed  Google Scholar 

  3. Savarino, E. et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis. Esophagus 30, 1–9 (2017).

    PubMed  Google Scholar 

  4. Visaggi, P. et al. Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024. Expert Opin. Pharmacother. 25, 2077–2088 (2024).

    Article  PubMed  Google Scholar 

  5. Patel, A., Laine, L., Moayyedi, P. & Wu, J. AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review. Gastroenterology 167, 1228–1238 (2024).

    Article  PubMed  Google Scholar 

  6. Spechler, S. et al. American Foregut Society white paper report on the use of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Foregut 5, 195–215 (2025).

    Article  Google Scholar 

  7. Iwakiri, K. et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J. Gastroenterol. 57, 267–285 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Visaggi, P. et al. Ambulatory pH-impedance findings confirm that grade B esophagitis provides objective diagnosis of gastroesophageal reflux disease. Am. J. Gastroenterol. 118, 794–801 (2023).

    Article  PubMed  Google Scholar 

  9. Barberio, B. et al. Comparison of acid-lowering drugs for endoscopy negative reflux disease: systematic review and network meta-analysis. Neurogastroenterol. Motil. 35, e14469 (2023).

    Article  PubMed  Google Scholar 

  10. Uemura, N. et al. Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study. Clin. Gastroenterol. Hepatol. 23, 748–757.e5 (2025).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

    Pierfrancesco Visaggi

  2. Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy

    Edoardo V. Savarino

Authors
  1. Pierfrancesco Visaggi
    View author publications

    Search author on:PubMed Google Scholar

  2. Edoardo V. Savarino
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Edoardo V. Savarino.

Ethics declarations

Competing interests

P.V. has received lecture or consultancy fees from Apogee Therapeutics, Alfasigma, Malesci, Dr Falk Pharma, Pharmaline and Sanofi. E.V.S. has received lecture or consultancy fees from Abbvie, Aboca, Abivax, Agave, AGPharma, Alfasigma, Apogee, Apoteca, AstraZeneca, Biosline, Bristol-Myers Squibb, CaDiGroup, Celltrion, Dr Falk, EG Stada Group, Eli Lilly, Fenix Pharma, Galapagos, Giuliani, Grunenthal, Johnson & Johnson, JB Pharmaceuticals, Innovamedica/Adacyte, Lionhealth, Malesci, Mayoly Biohealth, Montefarco, Nestlè, Novartis, Omega Pharma, Pfizer, PRO.MED.CS Praha a.s., Rafa, Reckitt Benckiser, Recordati, Sandoz, Sanofi/Regeneron, SILA, Takeda, Tillots and Unifarco.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Visaggi, P., Savarino, E.V. Potassium-competitive acid blockers for the management of gastroesophageal reflux disease. Nat Rev Gastroenterol Hepatol (2025). https://doi.org/10.1038/s41575-025-01166-5

Download citation

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41575-025-01166-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing